文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

2016年10月至2023年9月美国成人呼吸道合胞病毒相关住院负担

Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023.
PubMed 文献 · JAMA Netw Open · 2024-11-04
一句话结论2016-2023年美国成人RSV相关住院估计每年12.3万-19.3万例,ICU 2.44万-3.49万例,院内死亡4680-8620例,75岁及以上占住院45.6%。

本横断面研究利用RSV住院监测网络(RSV-NET)数据,覆盖12个州58个县约8%美国人口,纳入2016-2017至2022-2023七个监测季非妊娠成人(≥18岁)实验室确诊RSV住院病例16575例。调整检测敏感性和检测不足后外推全美,估计年住院数123000-193000例、ICU 24400-34900例、院内死亡4680-8620例。住院率随年龄升高,75岁及以上最高(2022-2023季244.7/10万至2017-2018季411.4/10万)。75岁及以上占住院45.6%、ICU 38.6%、院内死亡58.7%。作者认为提高老年人RSV疫苗接种有潜力减少相关住院和严重临床结局。

要点

  • 2016-2023年RSV-NET共16575例成人RSV住院,中位年龄70岁(IQR 58-81),女性9641例(58.2%)。
  • 排除受COVID-19影响的2020-2021和2021-2022季后,年住院率48.9/10万(2016-2017)至76.2/10万(2017-2018)。
  • 75岁及以上住院率最高:2022-2023季244.7/10万(95%CI 207.9-297.3),2017-2018季411.4/10万(95%CI 292.1-695.4)。
  • 估计年住院123000例(2016-2017)至193000例(2017-2018),年ICU 24400-34900例,年院内死亡4680例(2018-2019)至8620例(2017-2018)。
  • 75岁及以上占全部RSV住院45.6%(范围43.1%-48.8%)、ICU 38.6%(36.7%-41.0%)、院内死亡58.7%(51.9%-67.1%)。

适用人群与场景

  • RSV-NET覆盖12个州58个县约8%美国人口,纳入非妊娠、≥18岁、居住于监测辖区、RSV检测阳性的住院成人。
  • 排除妊娠成人;研究期间为2016-2017至2022-2023共7个监测季。

诊断标准与关键阈值

  • 实验室确诊RSV相关住院定义为住院前14天内或住院期间RSV检测阳性。

研究设计与关键结果

  • 研究设计:横断面研究,基于RSV-NET population-based监测平台,纳入2016-2017至2022-2023季16575例成人RSV住院(中位年龄70岁,IQR 58-81;女性9641例,58.2%)。
  • 住院率:2016-2017季48.9/10万(95%CI 33.4-91.5),2017-2018季76.2/10万(95%CI 55.2-122.7)。
  • 年龄分层住院率:18-49岁最低,2016-2017季8.6/10万(95%CI 5.7-16.8),2022-2023季13.1/10万(95%CI 11.0-16.1);≥75岁最高,2022-2023季244.7/10万(95%CI 207.9-297.3),2017-2018季411.4/10万(95%CI 292.1-695.4)。
  • 年住院估计:2016-2017季123000例(95%CI 84000-230000),2017-2018季193000例(95%CI 140000-311000)。
  • 年ICU入住估计:同两季分别为24400例(95%CI 16700-44800)和34900例(95%CI 25500-55600)。
  • 年院内死亡估计:2018-2019季4680例(95%CI 3570-6820),2017-2018季8620例(95%CI 6220-14090)。
  • ≥75岁人群占全部RSV住院45.6%(范围43.1%-48.8%)、ICU入住38.6%(36.7%-41.0%)、院内死亡58.7%(51.9%-67.1%)。

证据类型、等级与局限

  • 证据类型:基于RSV-NET的横断面研究,数据来自12个州58个县约8%美国人口。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,提高老年人RSV疫苗接种有潜力减少相关住院和严重临床结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Respiratory syncytial virus (RSV) infection can cause severe illness in adults. However, there is considerable uncertainty in the burden of RSV-associated hospitalizations among adults prior to RSV vaccine introduction.

OBJECTIVE: To describe the demographic characteristics of adults hospitalized with laboratory-confirmed RSV and to estimate annual rates and numbers of RSV-associated hospitalizations, intensive care unit (ICU) admissions, and in-hospital deaths.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the RSV Hospitalization Surveillance Network (RSV-NET), a population-based surveillance platform that captures RSV-associated hospitalizations in 58 counties in 12 states, covering approximately 8% of the US population. The study period spanned 7 surveillance seasons from 2016-2017 through 2022-2023. Included cases from RSV-NET were nonpregnant hospitalized adults aged 18 years or older residing in the surveillance catchment area and with a positive RSV test result.

EXPOSURE: Laboratory-confirmed RSV-associated hospitalization, defined as a positive RSV test result within 14 days before or during hospitalization.

MAIN OUTCOMES AND MEASURES: Hospitalization rates per 100 000 adult population, stratified by age group. After adjusting for test sensitivity and undertesting for RSV in adults hospitalized with acute respiratory illnesses, rates were extrapolated to the US population to estimate annual numbers of RSV-associated hospitalizations. Clinical outcome data were used to estimate RSV-associated ICU admissions and in-hospital deaths.

RESULTS: From the 2016 to 2017 through the 2022 to 2023 RSV seasons, there were 16 575 RSV-associated hospitalizations in adults (median [IQR] age, 70 [58-81] years; 9641 females [58.2%]). Excluding the 2020 to 2021 and the 2021 to 2022 seasons, when the COVID-19 pandemic affected RSV circulation, hospitalization rates ranged from 48.9 (95% CI, 33.4-91.5) per 100 000 adults in 2016 to 2017 to 76.2 (95% CI, 55.2-122.7) per 100 000 adults in 2017 to 2018. Rates were lowest among adults aged 18 to 49 years (8.6 [95% CI, 5.7-16.8] per 100 000 adults in 2016-2017 to 13.1 [95% CI, 11.0-16.1] per 100 000 adults in 2022-2023) and highest among adults 75 years or older (244.7 [95% CI, 207.9-297.3] per 100 000 adults in 2022-2023 to 411.4 [95% CI, 292.1-695.4] per 100 000 adults in 2017-2018). Annual hospitalization estimates ranged from 123 000 (95% CI, 84 000-230 000) in 2016 to 2017 to 193 000 (95% CI, 140 000-311 000) in 2017 to 2018. Annual ICU admission estimates ranged from 24 400 (95% CI, 16 700-44 800) to 34 900 (95% CI, 25 500-55 600) for the same seasons. Estimated annual in-hospital deaths ranged from 4680 (95% CI, 3570-6820) in 2018 to 2019 to 8620 (95% CI, 6220-14 090) in 2017 to 2018. Adults 75 years or older accounted for 45.6% (range, 43.1%-48.8%) of all RSV-associated hospitalizations, 38.6% (range, 36.7%-41.0%) of all ICU admissions, and 58.7% (range, 51.9%-67.1%) of all in-hospital deaths.

CONCLUSIONS AND RELEVANCE: In this cross-sectional study of adults hospitalized with RSV before the 2023 introduction of RSV vaccines, RSV was associated with substantial burden of hospitalizations, ICU admissions, and in-hospital deaths in adults, with the highest rates occurring in adults 75 years or older. Increasing RSV vaccination of older adults has the potential to reduce associated hospitalizations and severe clinical outcomes.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Havers FP, Whitaker M, Melgar M, et al. Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023. JAMA Netw Open. 2024. PMID: 39535791. doi:10.1001/jamanetworkopen.2024.44756

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。